Sign In
Buy RHHBY
$54.64
-0.630 (-1.14%)
At Close: Jul 31, 2026
Roche presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas
04:30pm, Monday, 08'th Dec 2025
Basel, 8 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new data highlighting the potential of Lunsumio® (mosunetuzumab) in earlier treatment lines for people living with differen
Roche’s Columvi combination shows sustained survival benefit at three-year follow up of pivotal phase III STARGLO study
08:00am, Monday, 08'th Dec 2025
Overall survival was twice as long for people treated with Columvi in combination with GemOx versus MabThera/Rituxan plus GemOx1 This Columvi combination is available off-the-shelf and could offer a p
Roche May Be Riding A Bit Too High, But Remains Interesting
02:27pm, Friday, 05'th Dec 2025
Roche has rallied on improved sentiment around the late-stage pipeline, but near-term risk/reward is less compelling given elevated expectations and thin 2026 catalysts. The upcoming persevERA read-ou
Orano Med Enters Next Phase of Collaboration With Roche
05:14am, Thursday, 04'th Dec 2025
CHÂTILLON, France--(BUSINESS WIRE)--Orano Med's collaboration with Roche to develop “two-step pretargeted radioimmunotherapy” (or PRIT) ready to advance into clinical development.
Wall Street Just Woke Up to Roche--Here's Why It Could Be Pharma's Next $10 Billion Breakout
06:50am, Monday, 01'st Dec 2025
Roche Holding AG (RHHBY) just clocked its strongest monthly performance since 1997âsurging 19% in Novemberâas investors piled in following a pair of major c
Roche - Despite Some Study Setbacks, Pipeline Gives Me Increasing Confidence
10:55pm, Sunday, 30'th Nov 2025
Roche (OTCQX:RHHBY) is upgraded to Buy, driven by strong 2025 performance, robust pipeline, and attractive valuation metrics. RHHBY faces major patent expiries, but new launches like Phesgo, Helimbra,
Veeva Announces Expanded Partnership with Roche
07:03am, Monday, 24'th Nov 2025
Veeva to deliver next generation customer engagement with agentic AI for Roche PLEASANTON, Calif. , Nov. 24, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Roche Pharmaceuticals
Trump's Tariffs Led These 2 Companies To Invest Billions in The US
12:24pm, Sunday, 23'rd Nov 2025
President Trump's reciprocal tariff policy has turned the international trade world on its head for any nation reliant on the US market.
PITTSBURGH--(BUSINESS WIRE)--KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company developing cutting-edge, multi-mechanistic oncolytic immunotherapies, today announced a clinical t
European Commission approves Roche's Lunsumio subcutaneous for relapsed or refractory follicular lymphoma
01:00am, Wednesday, 19'th Nov 2025
Basel, 19 November 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted conditional marketing authorisation of Lunsumio® (mosunetuzumab) subcutaneous (SC
Market bubbles cracking: Gold & defense stocks the go‑to strategy, says David Roche
09:50pm, Tuesday, 18'th Nov 2025
David Roche of Quantum Strategy told CNBC's Squawk Box Asia that bubbles in AI and credit markets are beginning to crack, posing serious economic risks. While he noted the fallout is unlikely to reach
RHHBY Reports Positive Phase III Data on Breast Cancer Drug
02:26pm, Tuesday, 18'th Nov 2025
Roche reports strong phase III lidERA results as giredestrant delivers meaningful iDFS gains over standard endocrine therapy.
Roche's $15 Billion Breast Cancer Pill Just Stunned the Market--But AstraZeneca Is Lurking
01:15pm, Tuesday, 18'th Nov 2025
Roche (RHHBY) just handed investors the kind of surprise that could be reshaping the mood around its pipeline. After a fresh late-stage win for its experimental
Roche Shares Rise After Breast-Cancer Pill Shows Positive Results in Trial
06:02am, Tuesday, 18'th Nov 2025
The drugmaker said the results for giredestrant open the door to adding a treatment option at an early stage of the cancer, when most patients are diagnosed.
Roche oral drug shown to keep breast cancer at bay, boosting shares
05:06am, Tuesday, 18'th Nov 2025
Roche's ROG.S experimental oral drug giredestrant has been shown to cut the risk of recurrence of a common form of breast cancer after surgery, boosting the company's shares and underpinning its tradi
